Rebus Holdings Inc (RBSH)

[blanka]

BINGO!!!
*** Sabby Investment fund facilitated the cash ($250,000) needed in order to get the filings straight.

*** Sabby Investment fund took 40% ownership into NSPX.

*** NSPX re-activated some of their patents end of March 2020.


Now ask yourself the question, why would all of the above happen and what is the hidden common dominator in all of the above? Increased demand, possibilities, opportunities and applicability for those patents perhaps?

http://inspyrtherapeutics.com/adenosine-a2-receptor-antagonist-market-to-grow-significantly

Publish Date: JAN ‘20

Quote:The Adenosine A2 Receptor Antagonist Market is witnessing growth due to the presence of large pool of patients and technological advancements.



Note that in this report Lewis and Clark Pharmaceuticals is mentioned as one of the key players. http://www.lncpharma.com

According to the latest quartly report, L&C Pharmaceuticals is still a subsidiary of NSPX.

Quote:As used in this Quarterly Report, unless the context otherwise requires, the words “we,” “us,” “our,” “the Company,” “Inspyr Therapeutics” and “registrant” refer to Inspyr Therapeutics, Inc. and our wholly owned subsidiary, Lewis & Clark Pharmaceuticals, Inc